Tredje AP fonden Increases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Tredje AP fonden increased its stake in Alnylam Pharmaceuticals by 63.3% during the first quarter, acquiring an additional 6,165 shares, bringing its total holdings to 15,907 shares valued at approximately $4.3 million.
• Analysts have given Alnylam Pharmaceuticals a consensus rating of "Moderate Buy", with price targets ranging from $268.00 to $500.00, reflecting diverse expectations on the stock's future performance.
• In related developments, CEO Yvonne Greenstreet sold 31,640 shares of the company for approximately $9.6 million, reducing her ownership by nearly 39% amid recent stock valuation movements.

Tredje AP fonden lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 63.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,907 shares of the biopharmaceutical company's stock after buying an additional 6,165 shares during the period. Tredje AP fonden's holdings in Alnylam Pharmaceuticals were worth $4,295,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $243,000. Orion Portfolio Solutions LLC raised its position in Alnylam Pharmaceuticals by 5.7% in the 4th quarter. Orion Portfolio Solutions LLC now owns 3,744 shares of the biopharmaceutical company's stock worth $881,000 after purchasing an additional 203 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $63,000. National Bank of Canada FI boosted its position in shares of Alnylam Pharmaceuticals by 9.0% in the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock worth $157,000 after purchasing an additional 55 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company's stock valued at $518,367,000 after buying an additional 59,597 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ:ALNY traded up $9.56 during trading on Friday, reaching $401.80. 1,780,984 shares of the stock traded hands, compared to its average volume of 1,028,799. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $402.43. The stock has a market cap of $52.39 billion, a P/E ratio of -162.67 and a beta of 0.25. The stock has a 50-day moving average of $318.24 and a two-hundred day moving average of $278.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 444.38%. The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. The business's revenue was up 20.2% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of a number of research analyst reports. BMO Capital Markets upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a report on Tuesday, June 24th. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a report on Friday. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an "overweight" rating in a report on Wednesday, July 16th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, Bank of America increased their price target on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a report on Friday, July 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $392.13.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,978,088. This represents a 28.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.